Healthcare and
Biopharmaceutical CVC

“Driving Innovation in
Healthcare and Biopharmaceuticals”

To uphold our corporate mission, “We enrich people’s lives by providing
superior products and services that our customers love and trust,” LOTTE Holdings has
established a Healthcare and Biopharmaceutical Corporate Venture Capital (CVC) in July 2024.

Our Mission

To fulfill our mission of improving people’s well-being and creating
a healthier world by supporting and investing in startup companies that are developing innovative healthcare technologies to save the lives of patients.

Creating Value

Through strategic investments in exceptional startups, the CVC aims to foster their growth and create value not only for the companies themselves but also for society as a whole. Leveraging the extensive capabilities of the LOTTE Group, including LOTTE Biologics and its global networks, LOTTE can support transformation of innovative ideas into practical solutions for current and emerging challenges in human health. LOTTE’s areas of support encompass technology, business development, manufacturing solutions, and more.

Priority Areas

As the corporate venture capital arm of LOTTE Holdings Co., Ltd.,
we priortize investments in promising startups that have business synergies with LOTTE Biologics, a LOTTE Group company. We plan to invest in companies in early and growth stages globally,
not limited to Japan, with a focus on the following areas:

The investment areas include:
  • Antibody drugs
  • Antibody-drug conjugates (ADCs)
  • Next generation modalities (nucleic acid medicines, regenerative medicine, gene therapy)
  • Complementary technologies that enhance advanced biopharmaceuticals, including linkers and payloads including anticancer agents.
Portfolio
nuvig therapeutics
Contact
contact_bio.cvc@lotte-hd.co.jp
©Lotte Holdings Co.,Ltd.